Long-term flare risk and remission rates did not differ between patients with well-controlled RA who tapered vs continued MTX therapy.

The phase 4, open-label AGILE trial compared the safety and efficacy of 60-, 45-, and 30-minute pegloticase infusions vs standard 120-minute protocols.

Long-awaited updates to the American College of Rheumatology's (ACR) guideline on systemic lupus erythematosus (SLE) ...

After the Eastern Cape Department of Health’s account with a crucial chemotherapy provider was suspended, patients were once again left at risk as the Port Elizabeth Provincial Hospital ran out of ...

A higher-titer ANA raises the suspicion that something more systemic may be going on,’ said Amanda Mixon, PA-C.

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in ...

Belimumab is linked to a reduced risk for all-cause mortality compared with azathioprine, methotrexate, and mycophenolate among patients with nonrenal SLE.

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Alvotech rated Hold after FDA setback for AVT05. Click for my look at ALVO stock prospects and what would make me upgrade it to Buy.

Analysis - The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For example, 10 years ago in Ethiopia and Kenya, cancer care was ...